Benzeno Sharon's Form 4 filing
Adaptive Biotechnologies Corp (ADPT) · filed Jun 30, 2026
- Accession no.
- 0001780854-26-000008
- Filed
- Jun 30, 2026
- Trade date
- Jun 26-29, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 5 derivative transactions. Open-market sales total $3.50M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Benzeno SharonCIK 0001780854 | Officer (Chief Commercial Ofc Imm Med) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | Common Stock | MOption exerciseAcquired | +11,034 | $12.14 | +$133,952.76 | 283,785 | Direct | |
| Jun 26, 2026 | Common Stock | SSaleDisposed | −11,034 | $21.00F2 | −$231,714 | 272,751 | Direct | |
| Jun 29, 2026 | Common Stock | MOption exerciseAcquired | +1,837 | $12.14 | +$22,301.18 | 274,588 | Direct | |
| Jun 29, 2026 | Common Stock | MOption exerciseAcquired | +24,944 | $8.46 | +$211,026.24 | 299,532 | Direct | |
| Jun 29, 2026 | Common Stock | MOption exerciseAcquired | +24,944 | $3.99 | +$99,526.56 | 324,476 | Direct | |
| Jun 29, 2026 | Common Stock | MOption exerciseAcquired | +51,570 | $8.12 | +$418,748.4 | 376,046 | Direct | |
| Jun 29, 2026 | Common Stock | SSaleDisposed | −154,768 | $21.14F3 | −$3,271,795.52 | 221,278 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | Common Stock | MOption exerciseDisposed | −11,034 | $0.00 | $0 | 1,837 | Direct | |
| Jun 29, 2026 | Common Stock | MOption exerciseDisposed | −1,837 | $0.00 | $0 | 0 | Direct | |
| Jun 29, 2026 | Common Stock | MOption exerciseDisposed | −24,944 | $0.00 | $0 | 37,416 | Direct | |
| Jun 29, 2026 | Common Stock | MOption exerciseDisposed | −24,944 | $0.00 | $0 | 87,303 | Direct | |
| Jun 29, 2026 | Common Stock | MOption exerciseDisposed | −51,570 | $0.00 | $0 | 113,457 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.01, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Referenced by the price of 1 transaction in Table I.